Semin Reprod Med 2010; 28(1): 081-090
DOI: 10.1055/s-0029-1242998
© Thieme Medical Publishers

Role of Progesterone in Endometrial Cancer

J. Julie Kim1 , Eloise Chapman-Davis1 , 2
  • 1Department Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois
  • 2Division of Gynecologic Oncology, Northwestern University, Chicago, Illinois
Further Information

Publication History

Publication Date:
26 January 2010 (online)


Progesterone is a key hormone in the endometrium that opposes estrogen-driven growth. Insufficient progesterone will result in unopposed estrogen action that could lead to the development of endometrial hyperplasia and adenocarcinoma. Although these endometrial neoplasias can regress in response to progestin treatment, this does not occur in all instances. To understand this resistance to progesterone and to improve on existing hormonal therapies, it is imperative that the molecular mechanisms of progesterone action through its receptor be deciphered in endometrial cancer. This review highlights what is known thus far regarding the efficacy of progestin therapy in the clinic and the role of progesterone in endometrial cancer cell behavior and gene regulation.


  • 1 Kurita T, Nakamura H. Embryology and Anatomy of the Uterus. 2nd ed. Newark, NJ; Harwood Academic 2007
  • 2 Clarke C L, Sutherland R L. Progestin regulation of cellular proliferation.  Endocr Rev. 1990;  11(2) 266-301
  • 3 Dockery P, Li T C, Rogers A W, Cooke I D, Lenton E A. The ultrastructure of the glandular epithelium in the timed endometrial biopsy.  Hum Reprod. 1988;  3(7) 826-834
  • 4 Wynn R M. Ultrastructural development of the human decidua.  Am J Obstet Gynecol. 1974;  118(5) 652-670
  • 5 Gellersen B, Brosens J. Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair.  J Endocrinol. 2003;  178(3) 357-372
  • 6 Mulac-Jericevic B, Mullinax R A, DeMayo F J, Lydon J P, Conneely O M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform.  Science. 2000;  289(5485) 1751-1754
  • 7 Gronemeyer H, Meyer M E, Bocquel M T, Kastner P, Turcotte B, Chambon P. Progestin receptors: isoforms and antihormone action.  J Steroid Biochem Mol Biol. 1991;  40(1-3) 271-278
  • 8 Kastner P, Krust A, Turcotte B et al.. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B.  EMBO J. 1990;  9(5) 1603-1614
  • 9 Lessey B A, Alexander P S, Horwitz K B. The subunit structure of human breast cancer progesterone receptors: characterization by chromatography and photoaffinity labeling.  Endocrinology. 1983;  112(4) 1267-1274
  • 10 Chi T, Lieberman P, Ellwood K, Carey M. A general mechanism for transcriptional synergy by eukaryotic activators.  Nature. 1995;  377(6546) 254-257
  • 11 Giangrande P H, Kimbrel E A, Edwards D P, McDonnell D P. The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding.  Mol Cell Biol. 2000;  20(9) 3102-3115
  • 12 McDonnell D P, Shahbaz M M, Vegeto E, Goldman M E. The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity.  J Steroid Biochem Mol Biol. 1994;  48(5-6) 425-432
  • 13 Tetel M J, Giangrande P H, Leonhardt S A, McDonnell D P, Edwards D P. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo.  Mol Endocrinol. 1999;  13(6) 910-924
  • 14 Tung L, Abdel-Hafiz H, Shen T et al.. Progesterone receptors (PR)-B and -A regulate transcription by different mechanisms: AF-3 exerts regulatory control over coactivator binding to PR-B.  Mol Endocrinol. 2006;  20(11) 2656-2670
  • 15 Tung L, Mohamed M K, Hoeffler J P, Takimoto G S, Horwitz K B. Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors.  Mol Endocrinol. 1993;  7(10) 1256-1265
  • 16 Vegeto E, Shahbaz M M, Wen D X, Goldman M E, O'Malley B W, McDonnell D P. Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function.  Mol Endocrinol. 1993;  7(10) 1244-1255
  • 17 Wagner B L, Norris J D, Knotts T A, Weigel N L, McDonnell D P. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor.  Mol Cell Biol. 1998;  18(3) 1369-1378
  • 18 Mangal R K, Wiehle R D, Poindexter III A N, Weigel N L. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle.  J Steroid Biochem Mol Biol. 1997;  63(4-6) 195-202
  • 19 Garcia E, Bouchard P, De Brux J et al.. Use of immunocytochemistry of progesterone and estrogen receptors for endometrial dating.  J Clin Endocrinol Metab. 1988;  67(1) 80-87
  • 20 Mylonas I, Jeschke U, Shabani N et al.. Steroid receptors ERalpha, ERbeta, PR-A and PR-B are differentially expressed in normal and atrophic human endometrium.  Histol Histopathol. 2007;  22(2) 169-176
  • 21 Snijders M P, de Goeij A F, Debets-Te Baerts M J, Rousch M J, Koudstaal J, Bosman F T. Immunocytochemical analysis of oestrogen receptors and progesterone receptors in the human uterus throughout the menstrual cycle and after the menopause.  J Reprod Fertil. 1992;  94(2) 363-371
  • 22 American Cancer Society .Cancer facts and figures. Atlanta, GA; American Cancer Society 2008
  • 23 Creasman W T. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment.  Semin Oncol. 1997;  24(1, Suppl 1) 140-150
  • 24 Münstedt K, Grant P, Woenckhaus J, Roth G, Tinneberg H R. Cancer of the endometrium: current aspects of diagnostics and treatment.  World J Surg Oncol. 2004;  2 24
  • 25 Sherman M E. Theories of endometrial carcinogenesis: a multidisciplinary approach.  Mod Pathol. 2000;  13(3) 295-308
  • 26 Gallup D G, Stock R J. Adenocarcinoma of the endometrium in women 40 years of age or younger.  Obstet Gynecol. 1984;  64(3) 417-420
  • 27 Trimble C L, Kauderer J, Zaino R et al.. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.  Cancer. 2006;  106(4) 812-819
  • 28 Reifenstein Jr E C. The treatment of advanced endometrial cancer with hydroxyprogesterone caproate.  Gynecol Oncol. 1974;  2(2-3) 377-414
  • 29 Saegusa M, Okayasu I. Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis.  Cancer. 1998;  83(1) 111-121
  • 30 Affinito P, Di Carlo C, Di Mauro P, Napolitano V, Nappi C. Endometrial hyperplasia: efficacy of a new treatment with a vaginal cream containing natural micronized progesterone.  Maturitas. 1994;  20(2-3) 191-198
  • 31 Clark T J, Neelakantan D, Gupta J K. The management of endometrial hyperplasia: an evaluation of current practice.  Eur J Obstet Gynecol Reprod Biol. 2006;  125(2) 259-264
  • 32 Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia.  Am J Obstet Gynecol. 1989;  160(1) 126-131
  • 33 Gal D, Edman C D, Vellios F, Forney J P. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia.  Am J Obstet Gynecol. 1983;  146(3) 316-322
  • 34 Varma R, Soneja H, Bhatia K et al.. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia—a long-term follow-up study.  Eur J Obstet Gynecol Reprod Biol. 2008;  139(2) 169-175
  • 35 Randall T C, Kurman R J. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.  Obstet Gynecol. 1997;  90(3) 434-440
  • 36 Wheeler D T, Bristow R E, Kurman R J. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins.  Am J Surg Pathol. 2007;  31(7) 988-998
  • 37 Ushijima K, Yahata H, Yoshikawa H et al.. Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.  J Clin Oncol. 2007;  25(19) 2798-2803
  • 38 Ramirez P T, Frumovitz M, Bodurka D C, Sun C C, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.  Gynecol Oncol. 2004;  95(1) 133-138
  • 39 Chiva L, Lapuente F, González-Cortijo L et al.. Sparing fertility in young patients with endometrial cancer.  Gynecol Oncol. 2008;  111(2, Suppl) S101-S104
  • 40 Kim Y B, Holschneider C H, Ghosh K, Nieberg R K, Montz F J. Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature.  Cancer. 1997;  79(2) 320-327
  • 41 Montz F J, Bristow R E, Bovicelli A, Tomacruz R, Kurman R J. Intrauterine progesterone treatment of early endometrial cancer.  Am J Obstet Gynecol. 2002;  186(4) 651-657
  • 42 Dhar K K, NeedhiRajan T, Koslowski M, Woolas R P. Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature.  Gynecol Oncol. 2005;  97(3) 924-927
  • 43 Jones K, Georgiou M, Hyatt D, Spencer T, Thomas H. Endometrial adenocarcinoma following the insertion of a Mirena IUCD.  Gynecol Oncol. 2002;  87(2) 216-218
  • 44 Kresowik J, Ryan G L, Van Voorhis B J. Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system.  Obstet Gynecol. 2008;  111(2 Pt 2) 547-549
  • 45 Kelley R M, Baker W H. Progestational agents in the treatment of carcinoma of the endometrium.  N Engl J Med. 1961;  264 216-222
  • 46 Piver M S, Barlow J J, Lurain J R, Blumenson L E. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma.  Cancer. 1980;  45(2) 268-272
  • 47 Decruze S B, Green J A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review.  Int J Gynecol Cancer. 2007;  17(5) 964-978
  • 48 Thigpen J T, Brady M F, Alvarez R D et al.. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group.  J Clin Oncol. 1999;  17(6) 1736-1744
  • 49 Markman M. Hormonal therapy of endometrial cancer.  Eur J Cancer. 2005;  41(5) 673-675
  • 50 Quinn M A, Cauchi M, Fortune D. Endometrial carcinoma: steroid receptors and response to medroxyprogesterone acetate.  Gynecol Oncol. 1985;  21(3) 314-319
  • 51 Ehrlich C E, Young P C, Stehman F B, Sutton G P, Alford W M. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium.  Am J Obstet Gynecol. 1988;  158(4) 796-807
  • 52 Leslie K K, Stein M P, Kumar N S et al.. Progesterone receptor isoform identification and subcellular localization in endometrial cancer.  Gynecol Oncol. 2005;  96(1) 32-41
  • 53 Fujimoto J, Ichigo S, Hori M, Nishigaki M, Tamaya T. Expression of progesterone receptor form A and B mRNAs in gynecologic malignant tumors.  Tumour Biol. 1995;  16(4) 254-260
  • 54 Arnett-Mansfield R L, deFazio A, Wain G V et al.. Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium.  Cancer Res. 2001;  61(11) 4576-4582
  • 55 Kumar N S, Richer J, Owen G, Litman E, Horwitz K B, Leslie K K. Selective down-regulation of progesterone re+Although+ceptor isoform B in poorly differentiated human endometrial cancer cells: implications for unopposed estrogen action.  Cancer Res. 1998;  58(9) 1860-1865
  • 56 Jongen V, Briët J, de Jong R et al.. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.  Gynecol Oncol. 2009;  112(3) 537-542
  • 57 Zheng W, Baker H E, Mutter G L. Involution of PTEN-null endometrial glands with progestin therapy.  Gynecol Oncol. 2004;  92(3) 1008-1013
  • 58 Mutter G L, Lin M C, Fitzgerald J T et al.. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.  J Natl Cancer Inst. 2000;  92(11) 924-930
  • 59 Francis L W, Lewis P D, Gonzalez D et al.. Progesterone induces nano-scale molecular modifications on endometrial epithelial cell surfaces.  Biol Cell. 2009;  101(8) 481-491
  • 60 Dai D, Wolf D M, Litman E S, White M J, Leslie K K. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors.  Cancer Res. 2002;  62(3) 881-886
  • 61 Ueda M, Fujii H, Yoshizawa K, Abe F, Ueki M. Effects of sex steroids and growth factors on migration and invasion of endometrial adenocarcinoma SNG-M cells in vitro.  Jpn J Cancer Res. 1996;  87(5) 524-533
  • 62 Smid-Koopman E, Blok L J, Kühne L C et al.. Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines.  J Soc Gynecol Investig. 2003;  10(1) 49-57
  • 63 Hanekamp E E, Kühne L M, Grootegoed J A, Burger C W, Blok L J. Progesterone receptor A and B expression and progestagen treatment in growth and spread of endometrial cancer cells in nude mice.  Endocr Relat Cancer. 2004;  11(4) 831-841
  • 64 Saito T, Mizumoto H, Tanaka R et al.. Overexpressed progesterone receptor form B inhibit invasive activity suppressing matrix metalloproteinases in endometrial carcinoma cells.  Cancer Lett. 2004;  209(2) 237-243
  • 65 Di Nezza L A, Jobling T, Salamonsen L A. Progestin suppresses matrix metalloproteinase production in endometrial cancer.  Gynecol Oncol. 2003;  89(2) 325-333
  • 66 Jaffe R C, Ferguson-Gottschall S D, Gao W, Beam C, Fazleabas A T. Histone deacetylase inhibition and progesterone act synergistically to stimulate baboon glycodelin gene expression.  J Mol Endocrinol. 2007;  38(3) 401-407
  • 67 Uchida H, Maruyama T, Nagashima T, Asada H, Yoshimura Y. Histone deacetylase inhibitors induce differentiation of human endometrial adenocarcinoma cells through up-regulation of glycodelin.  Endocrinology. 2005;  146(12) 5365-5373
  • 68 Uchida H, Maruyama T, Ono M et al.. Histone deacetylase inhibitors stimulate cell migration in human endometrial adenocarcinoma cells through up-regulation of glycodelin.  Endocrinology. 2007;  148(2) 896-902
  • 69 Ohta K, Maruyama T, Uchida H et al.. Glycodelin blocks progression to S phase and inhibits cell growth: a possible progesterone-induced regulator for endometrial epithelial cell growth.  Mol Hum Reprod. 2008;  14(1) 17-22
  • 70 Dai D, Kumar N S, Wolf D M, Leslie K K. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.  Am J Obstet Gynecol. 2001;  184(5) 790-797
  • 71 Ward E C, Hoekstra A V, Blok L J et al.. The regulation and function of the forkhead transcription factor, Forkhead box O1, is dependent on the progesterone receptor in endometrial carcinoma.  Endocrinology. 2008;  149(4) 1942-1950
  • 72 Goto T, Takano M, Albergaria A et al.. Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells.  Oncogene. 2008;  27(1) 9-19
  • 73 Shiozawa T, Nikaido T, Nakayama K, Lu X, Fujii S. Involvement of cyclin-dependent kinase inhibitor p27Kip1 in growth inhibition of endometrium in the secretory phase and of hyperplastic endometrium treated with progesterone.  Mol Hum Reprod. 1998;  4(9) 899-905
  • 74 Watanabe J, Watanabe K, Jobo T et al.. Significance of p27 as a predicting marker for medroxyprogesterone acetate therapy against endometrial endometrioid adenocarcinoma.  Int J Gynecol Cancer. 2006;  16(Suppl 1) 452-457
  • 75 Vereide A B, Kaino T, Sager G, Ørbo A. Scottish Gynaecological Clinical Trials Group . Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone.  Gynecol Oncol. 2005;  97(3) 740-750
  • 76 Paulssen R H, Moe B, Grønaas H, Orbo A. Gene expression in endometrial cancer cells (Ishikawa) after short time high dose exposure to progesterone.  Steroids. 2008;  73(1) 116-128
  • 77 Hanekamp E E, Kühne E C, Smid-Koopman E et al.. Loss of progesterone receptor may lead to an invasive phenotype in human endometrial cancer.  Eur J Cancer. 2002;  38(Suppl 6) S71-S72
  • 78 Davies S, Dai D, Wolf D M, Leslie K K. Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells.  J Soc Gynecol Investig. 2004;  11(7) 494-499
  • 79 Dai D, Litman E S, Schonteich E, Leslie K K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth.  J Steroid Biochem Mol Biol. 2003;  87(2-3) 123-131
  • 80 Davies S, Dai D, Feldman I, Pickett G, Leslie K K. Identification of a novel mechanism of NF-kappaB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2.  Gynecol Oncol. 2004;  94(2) 463-470
  • 81 Salih S M, Salama S A, Jamaluddin M et al.. Progesterone-mediated regulation of catechol-O-methyl transferase expression in endometrial cancer cells.  Reprod Sci. 2008;  15(2) 210-220
  • 82 Tamura M, Sebastian S, Yang S et al.. Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-kappa B.  J Biol Chem. 2002;  277(29) 26208-26216
  • 83 Yang S, Fang Z, Gurates B et al.. Stromal PRs mediate induction of 17beta-hydroxysteroid dehydrogenase type 2 expression in human endometrial epithelium: a paracrine mechanism for inactivation of E2.  Mol Endocrinol. 2001;  15(12) 2093-2105
  • 84 Lee K, Jeong J, Tsai M J et al.. Molecular mechanisms involved in progesterone receptor regulation of uterine function.  J Steroid Biochem Mol Biol. 2006;  102(1) 41-50
  • 85 Samalecos A, Gellersen B. Systematic expression analysis and antibody screening do not support the existence of naturally occurring progesterone receptor (PR)-C, PR-M, or other truncated PR isoforms.  Endocrinology. 2008;  149(11) 5872-5887

J. Julie KimPh.D. 

Assistant Professor, Division of Reproductive Biology Research, Department Obstetrics and Gynecology, Robert H. Lurie Comprehensive Cancer Center

Northwestern University, 303 E. Superior Street, 4-117, Chicago, IL 60611